In this complex scenario it is interesting to point out that both patients experienced visual loss 7 to 22 months after the administration of Enzalutamide, implying a role of AR blocking as a potential precipitating factor in LHON together with the prolonged effect of Leuprolide in reducing estrogen levels. Here, AR is linked to Leber hereditary optic neuropathy.